for the Period Ended 31 March 2024
Directors report | |
Balance sheet | |
Additional notes | |
Balance sheet notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 March 2024
Directors
The directors shown below have held office during the whole of the period from
1 April 2023
to
31 March 2024
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Intangible assets: | 3 |
|
|
Tangible assets: | 4 |
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Stocks: | 5 |
|
|
Debtors: | 6 |
|
|
Cash at bank and in hand: |
|
|
|
Total current assets: |
|
|
|
Creditors: amounts falling due within one year: | 7 |
(
|
(
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Provision for liabilities: |
(
|
(
|
|
Total net assets (liabilities): |
|
|
|
Capital and reserves | |||
Called up share capital: |
|
|
|
Profit and loss account: |
|
|
|
Total Shareholders' funds: |
|
|
The notes form part of these financial statements
The directors have chosen not to file a copy of the company's profit and loss account.
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 March 2024
Basis of measurement and preparation
Turnover policy
Tangible fixed assets depreciation policy
Intangible fixed assets amortisation policy
Other accounting policies
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
for the Period Ended 31 March 2024
Goodwill | Other | Total | |
---|---|---|---|
Cost | £ | £ | £ |
At 1 April 2023 |
|
|
|
Additions |
|
|
|
Disposals | |||
Revaluations | |||
Transfers | |||
At 31 March 2024 |
|
|
|
Amortisation | |||
At 1 April 2023 |
|
|
|
Charge for year |
|
|
|
On disposals | |||
Other adjustments | |||
At 31 March 2024 |
|
|
|
Net book value | |||
At 31 March 2024 |
|
|
|
At 31 March 2023 |
|
|
for the Period Ended 31 March 2024
Land & buildings | Plant & machinery | Fixtures & fittings | Office equipment | Motor vehicles | Total | |
---|---|---|---|---|---|---|
Cost | £ | £ | £ | £ | £ | £ |
At 1 April 2023 |
|
|
|
|||
Additions |
|
|
|
|||
Disposals | ||||||
Revaluations | ||||||
Transfers | ||||||
At 31 March 2024 |
|
|
|
|||
Depreciation | ||||||
At 1 April 2023 |
|
|
|
|||
Charge for year |
|
|
|
|||
On disposals | ||||||
Other adjustments | ||||||
At 31 March 2024 |
|
|
|
|||
Net book value | ||||||
At 31 March 2024 |
|
|
|
|||
At 31 March 2023 |
|
|
|
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Stocks |
|
|
Total |
|
|
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Trade debtors |
|
|
Other debtors |
|
|
Total |
|
|
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
£ | £ | |
Trade creditors |
|
|
Taxation and social security |
|
|
Other creditors |
|
|
Total |
|
|
Throughout 2023/24 HEAL.med CIC has continued to support the diabetes community and develop innovative education that would improve education at diagnosis for children and their families. Heal.med has developed and rolled out a school training pilot which has impacted over 1,000 school staff within Leicestershire providing them with high quality and certified diabetes education to help care for pupils within their school who have type one diabetes. The HEAL.med team has engaged in multiple conferences and transferred that knowledge to the wider expert community. The team has attended ISPAD 2023 and ATTD 2024, which are major conferences specifically for diabetes, allowing us to interact with the community of healthcare professionals and a structured and specialist environment. The team has also presented at the child health technology conference and attended events by similar charitable organisations to us. HEAL.med has continued to explore potential growth activities for the business, such as engaging international hospitals for research pilots and development. The team has engaged with a hospital in Australia and has run a successful pilot, which has positively impacted patients and their families in the region.
HEAL.med is undertaking a project with a major Med tech company to help improve delivery of their own content, specifically to a children focused audience. This allows us not only to interact directly with the community but to have information and support coming straight from the manufacturer, enabling accurate and relevant information from the source. The team has also engaged in summer camps and diabetes activities that involves the wider community, gathering feedback and making improvements to the services we provide. HEAL.med has also refreshed its board of non-executive directors for fresh advice and impact from a wider variety of stakeholders including NHS research and innovation, NHS staff and consultants.
HEAL.med CIC has paid remuneration to one director, for their time and efforts in managing the business on the day-to-day level. This paid time commitment was for three days per week (July 2023 to March 2024). Director: Lee Paxman-Clarke Remuneration= £10,848
No transfer of assets other than for full consideration
This report was approved by the board of directors on
24 July 2024
And signed on behalf of the board by:
Name: Mr L R Paxman-Clarke
Status: Director